Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.